EPS for Myriad Genetics, Inc. (MYGN) Expected At $0.34

Myriad Genetics, Inc. (NASDAQ:MYGN) Logo
Investors sentiment increased to 1.44 in Q3 2018. Its up 0.49, from 0.95 in 2018Q2. It increased, as 19 investors sold Myriad Genetics, Inc. shares while 70 reduced holdings. 55 funds opened positions while 73 raised stakes. 72.91 million shares or 2.53% more from 71.11 million shares in 2018Q2 were reported.
Sei Investments Commerce has invested 0.01% in Myriad Genetics, Inc. (NASDAQ:MYGN). Piedmont Investment reported 0.03% of its portfolio in Myriad Genetics, Inc. (NASDAQ:MYGN). Bnp Paribas Arbitrage holds 0% or 4,974 shares in its portfolio. Great West Life Assurance Co Can accumulated 0.01% or 89,198 shares. Dupont Cap Management invested 0.02% of its portfolio in Myriad Genetics, Inc. (NASDAQ:MYGN). Huntington Bancorp holds 0% or 198 shares. Rhumbline Advisers reported 161,991 shares. Creative Planning accumulated 5,783 shares. Louisiana State Employees Retirement Sys has 0.06% invested in Myriad Genetics, Inc. (NASDAQ:MYGN) for 31,300 shares. Public Employees Retirement Association Of Colorado has invested 0% in Myriad Genetics, Inc. (NASDAQ:MYGN). Axa reported 42,600 shares stake. Tiaa Cref Inv Limited Liability Company invested in 135,101 shares or 0% of the stock. Maryland-based Marathon has invested 0.09% in Myriad Genetics, Inc. (NASDAQ:MYGN). Next Financial holds 100 shares. D E Shaw & holds 0.22% of its portfolio in Myriad Genetics, Inc. (NASDAQ:MYGN) for 3.89M shares.

Analysts expect Myriad Genetics, Inc. (NASDAQ:MYGN) to report $0.34 EPS on February, 5.They anticipate $0.03 EPS change or 9.68 % from last quarter’s $0.31 EPS. MYGN’s profit would be $25.42M giving it 21.50 P/E if the $0.34 EPS is correct. After having $0.35 EPS previously, Myriad Genetics, Inc.’s analysts see -2.86 % EPS growth. The stock decreased 3.37% or $1.02 during the last trading session, reaching $29.24. About 540,376 shares traded. Myriad Genetics, Inc. (NASDAQ:MYGN) has declined 5.65% since January 14, 2018 and is downtrending. It has underperformed by 5.65% the S&P500.

Myriad Genetics, Inc. (NASDAQ:MYGN) Ratings Coverage

Among 9 analysts covering Myriad Genetics (NASDAQ:MYGN), 4 have Buy rating, 2 Sell and 3 Hold. Therefore 44% are positive. Myriad Genetics had 14 analyst reports since July 16, 2018 according to SRatingsIntel. As per Wednesday, August 22, the company rating was maintained by Bank of America. The rating was downgraded by Barclays Capital on Wednesday, September 5 to “Underweight”. Deutsche Bank maintained Myriad Genetics, Inc. (NASDAQ:MYGN) rating on Monday, November 5. Deutsche Bank has “Hold” rating and $43 target. Morgan Stanley maintained the stock with “Overweight” rating in Wednesday, August 22 report. The firm earned “Equal-Weight” rating on Wednesday, August 22 by Barclays Capital. On Thursday, January 3 the stock rating was maintained by Barclays Capital with “Underweight”. The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) has “Outperform” rating given on Friday, January 4 by Cowen & Co. The rating was maintained by Leerink Swann with “Market Perform” on Tuesday, August 28. The firm earned “Overweight” rating on Wednesday, October 10 by Morgan Stanley. PiperJaffray upgraded the stock to “Overweight” rating in Wednesday, October 10 report.

Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company has market cap of $2.19 billion. The firm offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It has a 41.3 P/E ratio. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer.

More notable recent Myriad Genetics, Inc. (NASDAQ:MYGN) news were published by: Benzinga.com which released: “Myriad Genetics (NASDAQ:MYGN) Spikes On Better-Than-Expected Q3 Print – Benzinga” on May 08, 2018, also Globenewswire.com with their article: “Bendcare Endorses Vectra® Testing for Patients with Rheumatoid Arthritis – GlobeNewswire” published on October 18, 2018, Globenewswire.com published: “Myriad Reschedules Release of Fiscal Fourth-Quarter 2018 Financial Results – GlobeNewswire” on August 13, 2018. More interesting news about Myriad Genetics, Inc. (NASDAQ:MYGN) were released by: Seekingalpha.com and their article: “Myriad announces $50M accelerated share repurchase program – Seeking Alpha” published on November 19, 2018 as well as Nasdaq.com‘s news article titled: “Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Pfizer’s TALZENNA® (talazoparib) – Nasdaq” with publication date: October 16, 2018.

Myriad Genetics, Inc. (NASDAQ:MYGN) Institutional Positions Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.